Peptide Linkers are developed as the critical component of ADC linkers which play vital roles in the overall success of the ADC. By introducing a PEG into the linker, it increases the water-solubility and helping finetune the drug DMPK. A well-designed linker helps the antibody to selectively deliver a cytotoxic drug to tumor cells and accurately releases the drug at tumor site. Two kinds of ADC linkers are used in current ADC drugs: cleavable linkers and non-cleavable linkers.
Featured products: PEG-Val-Cit, PEG-Val-Cit-PAB, Val-Cit-PAB-PNP, DBCO, BCN, Azide, Tetrazine, TCO, MMAE, DM1, DM4 and other payloads.
BroadPharm also offers customer-oriented ADC linker synthesis and services to our customers worldwide.